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Erythrocytes may play a role in glucose homeostasis during the
postprandial period. Erythrocytes from diabetic patients are defective
in glucose transport and metabolism, functions that may affect glyco-
gen storage. Phenobarbital, a hepatic enzyme inducer, has been used in
the treatment of patients with non-insulin-dependent diabetes mellitus
(NIDDM), increasing the insulin-mediated glucose disposal. We stud-
ied the effects of phenobarbital treatment i  vivo on glycemia and
erythrocyte glycogen content in control and alloxan-diabetic rats
during the postprandial period. In control rats (blood glucose, 73 to
111 mg/dl in femoral and suprahepatic veins) the erythrocyte glycogen
content was 45.4 ± 1.1 and 39.1 ± 0.8 µg/g Hb (mean ± SEM, N = 4-
6) in the femoral artery and vein, respectively, and 37.9 ± 1.1 in the
portal vein and 47.5 ± 0.9 in the suprahepatic vein. Diabetic rats (blood
glucose, 300-350 mg/dl) presented low (P<0.05) erythrocyte glycogen
content, i.e., 9.6 ± 0.1 and 7.1 ± 0.7 µg/g Hb in the femoral artery and
vein, respectively, and 10.0 ± 0.7 and 10.7 ± 0.5 in the portal and
suprahepatic veins, respectively. After 10 days of treatment, pheno-
barbital (0.5 mg/ml in the drinking water) did not change blood
glucose or erythrocyte glycogen content in control rats. In diabetic
rats, however, it lowered (P<0.05) blood glucose in the femoral artery
(from 305 ± 18 to 204 ± 45 mg/dl) and femoral vein (from 300 ± 11 to
174 ± 48 mg/dl) and suprahepatic vein (from 350 ± 10 to 174 ± 42 mg/
dl), but the reduction was not sufficient for complete recovery. Pheno-
barbital also stimulated the glycogen synthesis, leading to a partial
recovery of glycogen stores in erythrocytes. In treated rats, erythrocyte
glycogen content increased to 20.7 ± 3.8 µg/g Hb in the femoral artery
and 30.9 ± 0.9 µg/g Hb in the suprahepatic vein (P<0.05). These data
indicate that phenobarbital activated some of the insulin-stimulated
glucose metabolism steps which were depressed in diabetic erythro-
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Studies of carbohydrate metabolism and
glucose transport suggest that erythrocytes
play a role in glucose homeostasis. Similar
to other cells, they are equipped with the
glucose transporter identified as GLUT1
which is not regulated by hormones. GLUT1
has a low Km for glucose (~2 mM) when
assayed by zero-trans uptake. In situ, it ex-
hibits an asymmetric pattern of transport,
with a 4-fold higher Km for efflux compared
to influx (1). The glucose transporter of
erythrocyte may represent 3.5% of mem-
brane proteins (2). For energy production,
erythrocytes require glycolysis which is very
low (1.1 mmol h-1 l-1) in normoglycemic
humans (3). However, the uptake of glucose
exceeds by more than twelve thousand times
their metabolic requirement (4). This excess
is distributed to the periphery, which contri-
butes to glucose homeostasis, especially dur-
ing the postprandial period. Accordingly,
under hyperglycemic conditions, glucose is
taken up and released when glycemia falls
below normal values (5,6).
Glucose is stored in erythrocytes as gly-
cogen. Enzymes for glycogen synthesis and
breakdown have long been recognized in
normal erythrocytes (7,8). The b isoform of
glycogen synthase (UDP-glucose-glycogen
glycosyl transferase), the only form present
in erythrocytes, is exclusively activated by
glucose-6-phosphate. Following incubation
at 37oC, the glycogen content of erythro-
cytes from normal rats is linearly correlated
with increasing extracellular glucose con-
centrations (6). Glycostatic functions are af-
fected in diabetic erythrocytes. Reduction of
glucose transporter function (9), impairment
of glucose utilization and reduction of glu-
cose-6-phosphate production (10) have been
reported. During preliminary studies, we
found that erythrocytes from alloxan-dia-
betic rats have a low glycogen content, either
when freshly isolated or when incubated
with increasing glucose concentrations. All
of these changes reinforce the idea of a role
of erythrocytes in glucose homeostasis.
Carbohydrate and drug metabolism are
linked in hepatocytes. Several studies have
shown that an increased flux of glucose
through the pentose pathway improved glu-
cose metabolism. Phenobarbital, an inducer
of glucuronyltransferase, several forms of
cytochrome P-450 and many mixed-func-
tion oxidases have been employed (11,12) to
decrease the plasma insulin concentration
without changing fasting glucose levels and
to increase the glucose disposal rate in healthy
non-diabetic subjects. Combined therapy
utilizing phenobarbital and sulfonylurea was
beneficial to non-insulin-dependent diabetic
patients, enhancing the insulin-mediated glu-
cose disposal (13).
Since hepatocytes and erythrocytes, as
participants in glucose homeostasis, share
some properties related to glucose transport
and glycogen storage, we studied the effects
of phenobarbital treatment in vivo on glyce-
mia and glycogen content of erythrocytes
from normal and diabetic rats.
Adult male Wistar rats (3 months old)
were obtained from Centro de Bioterismo,
UNICAMP, Brazil, and housed at 22 ± 2oC,
under a 12-h light/dark cycle (lights on, 6:00
a.m.), receiving laboratory chow and water
ad libitum. One week later, their hemato-
logical parameters (blood cell count, hemat-
ocrit, hemoglobin concentration and glyce-
mia) were determined and found to be nor-
mal. Diabetes was induced by alloxan (40
mg/kg body weight, iv) in rats under ether
anesthesia and confirmed by the appearance
of glycosuria. One week later, control and
diabetic groups were divided into two fur-
her groups; one continued to receive plain
tap water (control and diabetic rats) and the
other received phenobarbital (0.5 mg/ml, for
10 days) in the drinking water (treated con-
trol and treated diabetic rats). Experiments
were performed with fed rats, 3 h after the
light was turned on and 1 h after food re-
moval. Rats were anesthetized with sodium
pentobarbital and 30 min later the right femo-
ral vein and artery were exposed and succes-
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sive blood samples (0.5 ml) were collected
from them. After laparotomy, blood was
also collected from the portal and suprahe-
patic veins, about 60 to 65 s after exposure of
the femoral artery. After centrifugation,
plasma was separated and used for determi-
nation of glycemia. Erythrocytes were resus-
pended two times in 0.9% saline solution
and the supernatant was discarded to avoid
leukocyte contamination. Plasma glucose
concentration was measured by an enzy-
matic method (Celm-Reactoclin) at 505 nm.
Hemoglobin concentration was measured
from a 20-µl aliquot of erythrocytes at 540
nm (Labtest). For the measurement of glyco-
gen content, a 200-µl aliquot of erythrocytes
was processed according to the method of
Farquharson et al. (14) which has a sensitiv-
ity of 0.1 µg and allows 90% glycogen re-
covery, with a detection limit of 5 µg/g Hb.
Amyloglycosidase, oyster glycogen and NAD
were obtained from Sigma (St. Louis, MO).
All other reagents were analytical grade.
Results are reported as mean ± SEM, N = 4-
6. The data for the arteriovenous and portal
and suprahepatic veins were analyzed statis-
tically by the paired Student t-test. The dif-
ferences between groups were analyzed sta-
tistically by one-way ANOVA followed by
the Tukey test.
Table 1 shows the glycemia of control,
diabetic and phenobarbital-treated rats. Gly-
cemia varied in control rats according to the
vessel sampled, showing an expected arte-
riovenous difference of 25% (P<0.05). These
results are compatible with peripheral glu-
cose utilization and in agreement with
Guarner and Alvarez-Buylla (6). Also, we
measured the difference between the portal
and suprahepatic veins, with glycemia in-
creasing by 15% (P<0.05) after blood had
crossed the liver. Glycemia was three times
higher in alloxan-diabetic rats than in the
control group and showed no arteriovenous
difference. However, glycemia in the supra-
hepatic vein was still higher than in the
portal vein (17%, P<0.05) due to the known
increased liver glucose output in the absence
f insulin. Phenobarbital treatment reduced
glycemia in the femoral artery and vein and
suprahepatic vein of diabetic rats (P<0.05),
although not enough to restore control val-
ues. The reduction in phenobarbital-induced
glycemia may correspond to a) an improve-
ment in peripheral glucose utilization as
shown by the 14.7% arteriovenous differ-
ence; b) a reduction of glucose output from
the liver (P<0.05) and c) an increase in glu-
cose uptake by the liver, erythrocytes and
skeletal muscles and consequently, an in-
crease in glycogen synthesis (as will be shown
below). Our results agree with studies con-
ducted on non-insulin-dependent diabetic
patients (13) and streptozotocin-diabetic rats
(15), showing that phenobarbital improved
the sensitivity of individuals to insulin by
reducing the fasting glycemia and increasing
the insulin-mediated glucose metabolism.
The latter effect (13) was closely correlated
with the rate of plasma antipyrine clearance,
n index of liver microsomal enzyme activ-
ity, suggesting that peripheral glucose utili-
zation and the liver microsomal system may
hare common regulators. Thus, stimulation
of the liver microsomal system by phenobar-
bital may be one of the key steps for the
reduction of glycemia in treated diabetic
rats.
Table 2 shows the glycogen content of
Table 1 - Effect of phenobarbital on serum glucose concentration of alloxan-diabetic
rats.
Treated rats received phenobarbital (0.5 mg/ml) for 10 days in drinking water. Data are
reported as mean ± SEM in mg/dl; N = 6 for control, treated control and diabetic rats
and N = 4 for treated diabetic rats. Data were analyzed statistically by ANOVA,
followed by the Tukey test. *P<0.05 compared to control and treated control groups
and +P<0.05 compared to untreated diabetic group.
Groups Femoral Femoral Portal Suprahepatic
artery vein vein vein
Control 97 ± 12.0 73 ± 3.4 96 ± 5.8 111 ± 4.3
Treated control 97 ± 2.9 89 ± 4.1 87 ± 2.9 97 ± 3.0
Diabetic 305 ± 18.0* 300 ± 11.0* 300 ± 19.0* 350 ± 10.0*
Treated diabetic 204 ± 45.0*+ 174 ± 48.0*+ 261 ± 46.0* 174 ± 42.0*+
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erythrocytes from control, diabetic and phe-
nobarbital-treated rats. Our results showed
differences in erythrocyte glycogen content
between the femoral artery and vein (~14%,
P<0.05) of both control and treated control
rats and between the portal and suprahepatic
vein (~26%, P<0.05) of controls alone. Dia-
betic rats had a low glycogen content, about
1/4 of the control. Following phenobarbital
treatment, the erythrocyte glycogen content
increased in the femoral artery and suprahe-
patic vein (P<0.05), but the recovery was
incomplete.
These results are in agreement with the
changes in glycemia induced by phenobarbi-
tal treatment (Table 1) and partially account
for the reduction of blood glucose. Our re-
sults may be compared to those reported for
the rectus muscle of streptozotocin-diabetic
rats (15) in which phenobarbital treatment
induced an increase in [3-3H]glucose incor-
poration into glycogen. Both effects may be
a consequence of the phenobarbital-induced
increase in insulin-mediated glucose utiliza-
tion. Phenobarbital is a classical activator of
the hepatic microsomal enzyme system
whose terminal component is cytochrome P-
450. This system is involved in the metabo-
lism of a variety of drugs, steroids and other
endogenous and exogenous compounds. It is
activated by NADPH and uridine diphos-
phate whose increase depends on the activ-
ity of glucose-6-phosphate dehydrogenase
and 6-phosphogluconate dehydrogenase via
the pentose pathway and cytosolic malic
enzymes (16). Phenobarbital also increases
hepatic glucokinase and hexokinase, enzymes
that phosphorylate glucose, and decreases
the activity of glucose-6-phosphatase, which
controls glucose release from the liver (17).
Phenobarbital has similar effects on skeletal
muscle from normally fed rats. In this prepa-
ration, a close correlation was found be-
tween glucose-6-phosphate concentrations,
determined as percent glycogen synthase in
the active I form whose conversion is insulin
dependent, and phosphatase activity (18).
The increase in glycogen content in erythro-
cytes from diabetic rats treated with pheno-
barbital may be the consequence of an in-
crease in glucose-6-phosphate concentration
which stimulates glycogen synthase b. Our
results suggest that erythrocytes play a role
in glucose homeostasis, contributing to its
storage and distribution and demonstrate that
the treatment with phenobarbital, a hepatic
enzyme inducer, partially restored erythro-
cyte glycogen content and reduced glycemia
in alloxan-diabetic rats.
Table 2 - Effect of phenobarbital on erythrocyte glycogen content of control and
alloxan-diabetic rats.
Treated rats received phenobarbital (0.5 mg/ml) for 10 days in drinking water. Data are
reported as mean ± SEM in µg/g hemoglobin; N = 6 for control, treated control and
diabetic rats and N = 4 for treated diabetic rats. Data were analyzed statistically by
ANOVA, followed by the Tukey test. *P<0.05 compared to control group and +P<0.05
compared to untreated diabetic group.
Groups Femoral Femoral Portal Suprahepatic
artery vein vein vein
Control 45.4 ± 1.1 39.1 ± 0.8 37.9 ± 1.1 47.5 ± 0.9
Treated control 44.7 ± 2.6 38.9 ± 3.2 37.0 ± 5.7 46.8 ± 1.4
Diabetic 9.6 ± 0.1* 7.1 ± 0.7* 10.0 ± 0.7* 10.7 ± 0.5*
Treated diabetic 20.7 ± 3.8+ 9.2 ± 2.8* 12.6 ± 2.7* 30.9 ± 0.9*+
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